Leadership Team

Democratizing the application of adult stem cell technologies for human health.

Abdulkader Rahmo, PhD.
Abdulkader Rahmo, PhD.
SMSbiotech
Co-Founder, President, CSO of SMSbiotech

Bachelor in biochemistry from the Swiss Federal Institute of Technology (ETH) in Zurich; Ph.D. in Biochemistry from the University of Southern California (USC) in Los Angeles and postdoc at a major clinical laboratory in Munich Germany.

As a former associate professor, he has over 30 years of experience in basic and applied research; 11 years primarily focused on SMS cell discovery, development, and technology. Experienced in clinical laboratory medicine, GXP compliance, and biomanufacturing. Co-Founded and lead several private and public entities including the National Commission for Biotechnology where he became the head of the medical Biotechnology section.

Harry Friedman
Harry Friedman
SMSbiotech
Chief Financial Officer

Seasoned Businessman, Investor, and Consultant Experienced Board Member. Self-financed a high-growth technology company which successfully sold, 20-plus years later, to a large conglomerate.

Started and participated in growing and selling several technology companies. Was a long-time member of Tech Coast Angels.

Roger Schechter, MD
Roger Schechter, MD
SMSbiotech
Clinical Research Director

FACEP, FCCWS, UHM-ABEM, Medical Director for Wound Management at Palomar Health San Diego, Chief Medical Officer at Synergy Wound Technology, trained in Emergency Medicine, practices full time as a Wound Care and Hyperbaric Medicine Physician, a national level speaker on wound care, advanced wound care modalities, and non-invasive vascular testing.

Board of Directors

We’re lucky to be supported by some of the best investors in the world.

Abdulkader Rahmo, PhD.

Abdulkader Rahmo, PhD.

SMSbiotech

Co-Founder, President, CSO of SMSbiotech

Ghassan Kassab, PhD

Ghassan Kassab, PhD

SMSbiotech

Founder / President / CSO of California Medical Innovations Institute

Harry Friedman

Harry Friedman

SMSbiotech

Chief Financial Officer

Joe Kiani

Joe Kiani

SMSbiotech

Co-founder and CEO of Masimo Corp.

Mohamed Diab

Mohamed Diab

SMSbiotech

Cofounder and Sr Research Scientist of Masimo Corp.

Advisors

We’re lucky to be supported by some of the best investors in the world.

Prof. Peter Wagner, MDProf. Peter Wagner, MD

Prof. Peter Wagner, MD

Advisor

Emeritus Prof. at UCSD, leader in Respiratory Physiology, served as the Pres. of the American Thoracic Society, Pres. of the American Physiological Society, and Division Chief of both Physiology and Pulmonary Critical Care at UCSD School of Medicine, and as both member and chair of National Institutes of Health study sections.

Prof. James Sherley, MDProf. James Sherley, MD

Prof. James Sherley, MD

Advisor

Former Associate Professor at MIT (nine years), founder and former director of the Adult Stem Cell Technology Center at the Boston Biomedical Research Institute (five years); currently founder and Director of Asymmetrex, LLC, Adjunct Associate Professor, Hematology-Oncology Department, Rhode Island Hospital Brown University.

Patrick Griffith, MD, MBAPatrick Griffith, MD, MBA

Patrick Griffith, MD, MBA

Advisor

Exec. Medical Director at Adventist Health, Heart & Vascular Institute. +25 yrs as Cardiac & Thoracic Surgeon. Served as Medical Director of Thoracic Surgery for Salinas Valley Healthcare Systems and Chief of Cardiac Surgery at Rideout Medical Center. Leonhardt Ventures Board Director, Board Member for Second Heart Assist, Stimcoremd, and Beall Center for Innovation & Entrepreneurship. UCI Dean’s Advisory Board Member.

Gary Sieck, Ph.D.Gary Sieck, Ph.D.

Gary Sieck, Ph.D.

Advisor

Prof. of Physiology at Mayo Clinic School of Medicine and Science. Studies focus on cell signaling mechanisms that underlie muscle performance, with a focus on regenerative processes that can improve acute and chronic disease conditions. He has published over 380 peer-reviewed papers and received multiple NIH grants over 37+ years.

Who We Are

SMSbiotech was founded based on its revolutionary adult stem cell research. Through a combination of hard work and over three decades of experience in research and applications, we have been able to patent a new platform technology.

Our technology will change the way the life science industry approaches the development of cells and drugs, leading to a wide spectrum of medical applications.

About us